Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-06-25

Clinical Trial Update: A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating abemaciclib in combination with sunitinib for metastatic renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sutent (sunitinib)
  • VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Brown University | Conditions: Renal Cell Carcinoma Metastatic | Phase 1 | Status: TERMINATED